Alexandrea E Hatcher1,2, Sonia Mendoza3,2, Helena Hansen2,4. 1. a Drug Policy Alliance , New York , New York , USA. 2. c Departments of Psychiatry and Anthropology , New York University , New York , New York , USA. 3. b Columbia University, Mailman School of Public Health, Sociomedical Sciences , New York , New York , USA. 4. d Nathan Kline Institute , Orangeburg, New York , USA.
Abstract
BACKGROUND/ OBJECTIVE: Office-based buprenorphine maintenance has been legalized and promoted as a treatment approach that not only expands access to care, but also reduces the stigma of addiction treatment by placing it in a mainstream clinical setting. At the same time, there are differences in buprenorphine treatment utilization by race, ethnicity, and socioeconomic status. METHODS: This article draws on qualitative data from interviews with 77 diverse patients receiving buprenorphine in a primary care clinic and two outpatient substance dependence clinics to examine differences in patients' experiences of stigma in relation their need for psychosocial supports and services. RESULTS: Management of stigma and perception of social needs varied significantly by ethnicity, race and SES, with white educated patients best able to capitalize on the medical focus and confidentiality of office-based buprenorphine, given that they have other sources of support outside of the clinic, and Black or Latino/a low income patients experiencing office-based buprenorphine treatment as isolating. CONCLUSION: Drawing on Agamben's theory of "bare life," and on the theory of intersectionality, the article argues that without attention to the multiple oppressions and survival needs of addiction patients who are further stigmatized by race and class, buprenorphine treatment can become a form of clinical abandonment.
BACKGROUND/ OBJECTIVE: Office-based buprenorphine maintenance has been legalized and promoted as a treatment approach that not only expands access to care, but also reduces the stigma of addiction treatment by placing it in a mainstream clinical setting. At the same time, there are differences in buprenorphine treatment utilization by race, ethnicity, and socioeconomic status. METHODS: This article draws on qualitative data from interviews with 77 diverse patients receiving buprenorphine in a primary care clinic and two outpatient substance dependence clinics to examine differences in patients' experiences of stigma in relation their need for psychosocial supports and services. RESULTS: Management of stigma and perception of social needs varied significantly by ethnicity, race and SES, with white educated patients best able to capitalize on the medical focus and confidentiality of office-based buprenorphine, given that they have other sources of support outside of the clinic, and Black or Latino/a low income patients experiencing office-based buprenorphine treatment as isolating. CONCLUSION: Drawing on Agamben's theory of "bare life," and on the theory of intersectionality, the article argues that without attention to the multiple oppressions and survival needs of addictionpatients who are further stigmatized by race and class, buprenorphine treatment can become a form of clinical abandonment.
Authors: Declan T Barry; Kevin S Irwin; Emlyn S Jones; William C Becker; Jeanette M Tetrault; Lynn E Sullivan; Helena Hansen; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin Journal: J Pain Date: 2010-06-02 Impact factor: 5.820
Authors: Joshua D Lee; Ellie Grossman; Andrea Truncali; John Rotrosen; Andrew Rosenblum; Stephen Magura; Marc N Gourevitch Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: Helena B Hansen; Carole E Siegel; Brady G Case; David N Bertollo; Danae DiRocco; Marc Galanter Journal: J Behav Health Serv Res Date: 2013-07 Impact factor: 1.505
Authors: Briony Larance; Natacha Carragher; Richard P Mattick; Nicholas Lintzeris; Robert Ali; Louisa Degenhardt Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492
Authors: Sydney M Silverstein; Raminta Daniulaityte; Shannon C Miller; Silvia S Martins; Robert G Carlson Journal: Drug Alcohol Depend Date: 2020-03-16 Impact factor: 4.492
Authors: Mariah M Kalmin; David Goodman-Meza; Erik Anderson; Ariana Abid; Melissa Speener; Hannah Snyder; Arianna Campbell; Aimee Moulin; Steve Shoptaw; Andrew A Herring Journal: Drug Alcohol Depend Date: 2021-03-18 Impact factor: 4.492
Authors: Kelly E Anderson; Brendan Saloner; Julia Eckstein; Christine E Chaisson; Sarah H Scholle; Lauren Niles; Sydney Dy; G Caleb Alexander Journal: Med Care Date: 2021-05-01 Impact factor: 3.178